Michael Hallek to Protein Kinase Inhibitors
This is a "connection" page, showing publications Michael Hallek has written about Protein Kinase Inhibitors.
Connection Strength
1.545
-
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6.
Score: 0.383
-
New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia. 2019 03; 33(3):576-587.
Score: 0.372
-
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018; 12:2577-2590.
Score: 0.360
-
Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):338-345.
Score: 0.343
-
Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018 12; 58:7-13.
Score: 0.023
-
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. Biomed Res Int. 2018; 2018:1023490.
Score: 0.022
-
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018 01 15; 142(2):322-333.
Score: 0.021
-
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue. Br J Haematol. 2017 09; 178(6):949-953.
Score: 0.021